SCHEMBL2579096

SCHEMBL2579096

CCOc1ccc(Cc2ccc(CC)cc2)cc1[C@@]1(O)C[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 6/20 0.54
CYP3A4 P08684 2/20 0.36
OPRK1 P41145 2/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
SLC5A1 P13866 2/20 0.35
BCHE P06276 2/20 0.34
ACHE P22303 2/20 0.34
TACR2 P21452 2/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
GAA P10253 1/20 0.31
MAPK10 P53779 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2575146 1.00 SLC5A2 (0.54) SLC5A2CYP3A4OPRK1OPRM1OPRD1
SCHEMBL2583629 0.88 SLC5A2 (0.41) SLC5A2CYP3A4SLC5A1BCHEACHE
SCHEMBL2579069 0.88 SLC5A2 (0.41) SLC5A2CYP3A4SLC5A1BCHEACHE
SCHEMBL2578498 0.80 SLC5A2 (0.54) SLC5A2CYP3A4SLC5A1BCHEACHE
SCHEMBL2578580 0.80 SLC5A2 (0.54) SLC5A2CYP3A4SLC5A1BCHEACHE
SCHEMBL12152960 0.77 ACHE (0.40) SLC5A2OPRM1SLC5A1BCHEACHE
SCHEMBL12152959 0.77 ACHE (0.40) SLC5A2OPRM1SLC5A1BCHEACHE
SCHEMBL2577495 0.77 CNR2 (0.38) BCHEACHEMEN1KMT2AGAA
SCHEMBL2578925 0.76 LTA4H (0.39) SLC5A2SLC5A1BCHEACHEMEN1
SCHEMBL1539258 0.72 SLC5A2 (0.37) SLC5A2SLC5A1TACR2GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 SLC5A2 3/4885CYP3A4 300/4885OPRK1 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.